Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 4:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Immunologic Disease Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

PrEP Intervention in Prince George's County, Maryland

NCT06141408
View directory record Official record
Conditions
Hiv, Mental Health Issue, Support, Family
Interventions
MPowerment PrEP Promotion Intervention
Behavioral
Lead sponsor
George Mason University
Other
Eligibility
18 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 17, 2026, 4:09 AM EDT
Not yet recruiting Phase 1 Interventional

A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia

NCT07283640
View directory record Official record
Conditions
Blinatumomab, Revumenib, Lymphoblastic Leukemia, KMT2A-rearranged
Interventions
Revumenib, Blinatumomab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 4 Interventional Results available

Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV

NCT00527618
View directory record Official record
Conditions
Genital Herpes, HIV Infection
Interventions
valacyclovir, acyclovir
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Sep 17, 2026, 4:09 AM EDT
Approved For Marketing No phase listed Expanded access

Treatment of Angioedema Attacks in Adolescent and Adult Patients 12 Years and Older With HAE Type I or II With Sebetralstat

NCT06628713
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Sebetralstat
Drug
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Industry
Eligibility
12 Years and older
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Sep 17, 2026, 4:09 AM EDT
Recruiting Not applicable Interventional

HIV Treatment Adherence Dose Determination Trial

NCT04577313
View directory record Official record
Conditions
HIV Infections
Interventions
Behavioral Self-Regulation Adherence Counseling
Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Storrs, Connecticut • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Sep 17, 2026, 4:09 AM EDT
Terminated Phase 2 Interventional Results available

Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies

NCT01745913
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Acute Lymphocytic Leukemia, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
Interventions
CliniMACS® CD34 Reagent System, Fludarabine, Melphalan, Rabbit ATG, Double Umbilical Cord Blood Transplantation, Haplo-Identical Cord Transplantation
Device · Drug · Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Sep 17, 2026, 4:09 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)

NCT04315324
View directory record Official record
Conditions
Recurrent T Acute Lymphoblastic Leukemia, Refractory T Acute Lymphoblastic Leukemia, Refractory T Lymphoblastic Lymphoma, T Lymphoblastic Lymphoma
Interventions
AKR1C3-activated Prodrug AST-3424, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Computed Tomography
Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
12 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
163
States / cities
Birmingham, Alabama • Kingman, Arizona • Little Rock, Arkansas + 94 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety, Tolerability, and Immunogenicity of a Prime-Boost Regimen of HIV-1 Nef/Tat/Vif, Env pDNA Vaccine Delivered Intramuscularly With Electroporation and HIV-1 rVSV envC Vaccine in Healthy, HIV-Uninfected Adults

NCT02654080
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-1 nef/tat/vif, env pDNA vaccine, rVSV HIV envC vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
2
States / cities
Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Sep 17, 2026, 4:09 AM EDT
Active, not recruiting No phase listed Observational

Using NLP and Neural Networks to Autonomously Identify Severe Asthma and Determine Study Eligibility in a Large Healthcare System

NCT06389058
View directory record Official record
Conditions
Severe Asthma
Interventions
Recommendation for the diagnoses and treatment of Severe Asthma
Other
Lead sponsor
San Diego State University
Other
Eligibility
6 Years to 85 Years
Enrollment
31,795 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients

NCT05222555
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma
Interventions
Tafasitamab, Lenalidomide
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 99 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Morristown, New Jersey • Dallas, Texas • Olympia, Washington
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma

NCT04257578
View directory record Official record
Conditions
B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
Interventions
Acalabrutinib, Axicabtagene Ciloleucel
Drug · Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 4 Interventional

Fexofenadine HCl 180 mg, Desloratadine 5 mg and Placebo in Suppression of Wheal and Flare Induced by Histamine

NCT00637585
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Fexofenadine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 10, 2011 · Synced Sep 17, 2026, 4:09 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Trial of Treatment of Atopic Dermatitis With Concurrent Altabax® and Topical Low-Potency Corticosteroids Versus Low-Potency Corticosteroid Mono-therapy

NCT00871208
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Altabax (R), Vehicle and Locoid lipocream (R)
Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
9 Months to 17 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2015 · Synced Sep 17, 2026, 4:09 AM EDT
Recruiting Phase 1 Interventional

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

NCT06859008
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Nodal Marginal Zone Lymphoma, Recurrent Splenic Marginal Zone Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Nodal Marginal Zone Lymphoma, Refractory Splenic Marginal Zone Lymphoma
Interventions
Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging, Questionnaire Administration, Sonrotoclax, Zanubrutinib
Procedure · Other · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Not applicable Interventional

Multisystemic Therapy to Reduce Health Disparities in Adolescents With Asthma

NCT00916240
View directory record Official record
Conditions
Asthma
Interventions
Multisystemic Therapy, Home-based, Non-Directive Family Support
Behavioral
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
12 Years to 16 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 18, 2016 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)

NCT01332968
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Bendamustine, Rituximab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
12
States / cities
Springdale, Arkansas • Irvine, California • Post Falls, Idaho + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Sep 17, 2026, 4:09 AM EDT
Terminated Phase 1 Interventional

RTA 744 Injection in Patients With Leptomeningeal Disease

NCT00512460
View directory record Official record
Conditions
Neoplastic Meningitis, Solid Tumor, Lymphoma, Leukemia, Brain Tumor
Interventions
RTA 744
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2016 · Synced Sep 17, 2026, 4:09 AM EDT
Terminated Phase 2 Interventional Results available

An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus

NCT03407482
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
GDC-0853
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 76 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
11
States / cities
Los Alamitos, California • Boca Raton, Florida • Brandon, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 17, 2026, 4:09 AM EDT
Completed No phase listed Observational

Evaluation of MyoStrain™ in Clinical Practice

NCT03825224
View directory record Official record
Conditions
Cardiac Failure, Coronary Artery Disease, Sarcoidosis, Amyloidosis, Lupus, Myocarditis, Drug Toxicity
Interventions
Diagnostic Test: Myostrain
Procedure
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
Not listed
Enrollment
19 participants
Timeline
2019
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Sep 17, 2026, 4:09 AM EDT
Terminated Phase 3 Interventional Results available

Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)

NCT02907177
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ponesimod, Placebo
Drug · Other
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 55 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
26
States / cities
Birmingham, Alabama • Fresno, California • Pasadena, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Sep 17, 2026, 4:09 AM EDT
Withdrawn Phase 4 Interventional

Impact of Sirolimus and Maraviroc on CCR5 Expression and the HIV-1 Reservoir in HIV-infected Kidney Transplant Recipients

NCT02990312
View directory record Official record
Conditions
Hiv, Kidney Transplant, HIV Reservoir, CCR5
Interventions
Sirolimus + Maraviroc
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 15, 2019 · Synced Sep 17, 2026, 4:09 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Clinic-Community Bridge to Improve Health Outcomes for Abused Women Living With HIV/AIDS

NCT07553312
View directory record Official record
Conditions
Adult Women Living With HIV/AIDS, Intimate Partner Violence
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Female only
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Terminated Phase 1 Interventional

Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients

NCT03876028
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Tisagenlecleucel, Ibrutinib
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Tampa, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 1 Interventional

A Pharmacokinetic Study of L-697,661 Alone and in Combination With Zidovudine

NCT00000628
View directory record Official record
Conditions
HIV Infections
Interventions
L-697,661, Zidovudine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
San Francisco, California • Denver, Colorado • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2008 · Synced Sep 17, 2026, 4:09 AM EDT